Drug Database
BE
bevacizumab (Stivant / BE 1040V / BE1040V)
✓ ApprovedAryoGen Pharmed · VEGFA · Monoclonal Antibodies
What is bevacizumab?
bevacizumab is a monoclonal antibodies developed by AryoGen Pharmed. It is approved for therapeutic indications via injectable (others) or intravenous (iv).
Drug Profile
| Brand Names | Stivant, BE 1040V, BE1040V |
| Company | AryoGen Pharmed |
| Drug Class | Monoclonal Antibodies, Antibody |
| Molecular Target | VEGFA |
| Route | Injectable (Others), Intravenous (IV) |
| Status | Approved |
Sources: ClinicalTrials.gov, AryoGen Pharmed
Mechanism of Action
Molecular Targets
bevacizumab acts on 1 molecular target:
| VEGFA | vascular endothelial growth factor A (VPF, MVCD1) |
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.
Therapeutic Indications
bevacizumab is developed for 9 unique indications across 2 therapeutic areas.
| Therapeutic Area | Condition | Phase |
|---|---|---|
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Brain neoplasm malignant | ✓ Approved |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Breast cancer | ✓ Approved |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Fallopian tube cancer | ✓ Approved |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Non-small cell lung cancer stage IV | ✓ Approved |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Ovarian cancer | ✓ Approved |
+4 more indications available with a free account
Sign up free to view all indications →Related Research Articles
Unable to load articles right now.